Introducing a new prescription therapeutic treatment for low bone density
Treating osteopenia is a difficult challenge for clinicians. Most pharmaceutical options are generally indicated for osteoporosis, by which time the damage is already done. Osteoboost is a Class II De Novo Breakthrough Device—the first FDA-cleared prescription medical device proven to reduce the loss of bone density, and the first therapeutic (drug or device) ever cleared specifically to treat osteopenia.
READ THE WHITE PAPERDOWNLOAD PRESCRIPTION FORM
Clinically-proven efficacy
In a pivotal clinical trial, Osteoboost demonstrated an 83% reduction in loss of bone strength in the spine, 85% reduction in loss of bone density in the spine, and 55% reduction in loss of bone density in the hip.*
Read the clinical trial results*(Results for study participants who used the device at least 3 times per week.)
High patient compliance
Adherence to the test protocol was 80%. Study completers averaged 4 sessions/week. When asked how easy was it to find time to use the belt 5x/week (on 10-point scale), trial participants rated it 7.8.
Read about patient compliance
No device-related serious adverse events
In the clinical trial, side effects were generally mild/moderate, commonly experienced conditions for older adults, transient, and resolved after temporarily stopping use.
Learn about possible side effects and warningsClinical trial manuscript to be published soon
Our randomized, double-blinded, sham-controlled clinical trial, led by Dr. Laura Bilek, PT, PhD at the University of Nebraska Medical Center, was designed with FDA input to evaluate the safety and effectiveness of Osteoboost therapy on bone strength and density in postmenopausal women with osteopenia.
The research abstract has been published in JES. The full manuscript has been accepted for publication. In the meantime, we have published a white paper highlighting key study results.
How to use Osteoboost with your patients
Integrate Osteoboost into your treatment protocol for patients with low bone density and track their success. Details for prescribing Osteoboost will be available soon.
1
SCHEDULE AN APPOINTMENT
Invite patients at risk for, or diagnosed with, osteopenia to schedule an appointment (phone or office) to discuss the treatment protocol.
2
GET A BASELINE DEXA
If the patient hasn’t had a recent scan, order a DEXA, REMS, or CT scan to establish a patent baseline. Then redo the same test every other year to track progress and adjust treatment schedule.
3
PRESCRIBE OSTEOBOOST
Prescribe Osteoboost to prevent further progression of the disease. Patients can share compliance records with physicians too. Download prescription form.